This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Amarin or Arena Takeout?

@glopolon asks, "$ARNA = $AFFY? More or less?"

Affymax (AFFY) shares dropped from $14 to $10 in the two weeks after FDA approved Omontys, a once-monthly anemia drug, this past spring. The stock has recovered a bit but is still down about 6% since Omontys' approval. So, yeah, Arena and Affymax are acting in similar ways post-drug approval.

Takeda sells Omontys on behalf of Affymax but how the product's sales will be reported publicly each quarter is not yet clear. Affymax spokeswoman Sylvia Wheeler told me that the company and Takeda are still working through the disclosure process. Affymax reports third-quarter financials in August.

Regarding Ampio Pharmaceuticals (AMPE) and the looming expiration of an insider stock lockup, Joe remarks, "Funny that the CEO and CSO's press release regarding voluntary extension of their lock-up was not followed by an SEC filing. I get the sense that AMPE's CEO and CSO might very well change their minds and not inform the shareholders. That press release is meaningless."

Good point. Even if Ampio's CEO and CSO do extend their lock-up agreement for another six months, plenty of other company insiders remain free to sell millions of shares starting July 15.

James asks, "Any chance you are going to take another look at Nymox Pharmaceuticals (NYMX)?"

Nymox remains opaque about the clinical development of NX-207, its experimental drug for benign prostatic hyperplasia, or enlarged prostate. When I last wrote about Nymox in February 2011, CEO Paul Averbeck told me he expected to file NX-207 for FDA approval in 2012, assuming the ongoing phase III studies were positive.

But since Nymox doesn't provide any meaningful updates about the progress of the phase III trials, it's impossible to say whether the company is on track to meet its development timelines for NX-207. I have my serious doubts, particularly since Nymox has never disclosed much about the drug, and what it has disclosed makes little sense.

Why trust a drug company unwilling to be transparent with its shareholders or potential investors?

Andrew I. asks, "Will Chelsea Therapeutics (CHTP) ever recover? Lost half of the value today and have to do a new study. Down to about 85 cents today. Think a lot of the bad news was already priced in and that this news is really not a surprise. I can understand why the company would try to re-work their current study 306B but not surprised at all the FDA said no deal. What are your thoughts?"
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AFFY $0.08 -9.60%
AMRN $1.67 -7.20%
ARNA $1.56 -1.30%
FOLD $6.69 -1.80%
VRTX $83.46 3.50%


Chart of I:DJI
DOW 17,711.90 +60.64 0.34%
S&P 500 2,057.23 +6.11 0.30%
NASDAQ 4,738.7810 +13.1420 0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs